PepGen Inc.
Pitch Summary: PepGen Inc. is advancing its DM1 treatment into phase 2 trials after reporting strong phase 1 results. However, the discontinuation of its DMD trials and the need for significant additional funding pose substantial risks. The company’s current market cap of $350 million, against a potential market size of $2.35-5.35 billion, suggests a limited […]
